Login to Your Account

Other News To Note

Thursday, April 14, 2011
Seattle Genetics Inc., of Bothell, Wash., announced that 10 programs using the company's antibody-drug conjugate (ADC) technology are now in clinical development across its 11 current ADC collaborations. That includes two additional ADC programs for which investigational new drug applications were recently submitted to the FDA by Genentech, a member of the Roche Group, of Basel, Switzerland, triggering milestone payments to Seattle Genetics.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription